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Abstract
E-cadherin is a main component of the cell-cell adhesion junctions that play a principal role in maintaining normal
breast epithelial cell morphology. Breast and other cancers that have up-regulated activity of Ras are often found to
have down-regulated or mislocalized E-cadherin expression. Disruption of E-cadherin junctions and consequent gain
of cell motility contribute to the process known as epithelial-to-mesenchymal transition (EMT). Enforced expression
of E-cadherin or inhibition of Ras-signal transduction pathway has been shown to be effective in causing reversion of
EMT in several oncogene-transformed and cancer-derived cell lines. In this study, we investigated MCF10A human
breast epithelial cells and derivatives that were transformed with either activated H-Ras or N-Ras to test for the re-
version of EMT by inhibition of Ras-driven signaling pathways. Our results demonstrated that inhibition of mitogen-
activated protein kinase (MAPK) kinase, but not PI3-kinase, Rac, or myosin light chain kinase, was able to completely
restore E-cadherin cell-cell junctions and epithelial morphology in cell lines with moderate H-Ras expression. In
MCF10A cells transformed by a high-level expression of activated H-Ras or N-Ras, restoration of E-cadherin junction
required both the enforced reexpression of E-cadherin and suppression of MAPK kinase. Enforced expression of
E-cadherin alone did not induce reversion from the mesenchymal phenotype. Our results suggest that Ras transfor-
mation has at least two independent actions to disrupt E-cadherin junctions, with effects to cause both mislocaliza-
tion of E-cadherin away from the cell surface and profound decrease in the expression of E-cadherin.
Neoplasia (2008) 10, 1444–1458
Introduction
In normal breast tissue, the epithelial cells form polarized, tubuloductal
structures that can further differentiate into alveoli that are functional
for lactation. The organization of the mammary epithelium is depen-
dent on maintenance of cell-cell adherens junctions that are mediated
by homotypic interactions between E-cadherin glycoproteins on ad-
jacent cells [1]. As the prototypical classic cadherin, E-cadherin is a
calcium-dependent intercellular adhesion molecule that couples to the
actin cytoskeleton through β-catenin, which binds to its cytoplasmic tail
[2]. In addition to its structural role in directing cellular adhesions,
E-cadherin also controls the ability of β-catenin to operate as a transcrip-
tion factor by regulating its subcellular localization [3].
There is a complex relationship between E-cadherin and the de-
velopment and progression of breast cancer [1]. E-cadherin may
function as a tumor suppressor in lobular breast cancer, as there is
commonly early loss of E-cadherin expression in this disease, in-
cluding by germ line mutation [1,4]. In ductal breast carcinomas,
E-cadherin expression is more variable [1], but there is evidence that
it may be lost from metastases even if maintained in the primary
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tumor [5]. Loss of functional E-cadherin contributes to a process
called epithelial-to-mesenchymal transition (EMT), in which epithe-
lial cells undergo loss of cell-cell adhesion and contact inhibition of
proliferation and gain of function in motility and invasiveness [6].
Loss of functional E-cadherin expression can result not only from
mutation but also more commonly from reversible transcriptional
suppression [7,8] or mislocalization from the cell surface [9,10].
The localization of E-cadherin is determined by polarized traffick-
ing of E-cadherin to the cell surface and by subsequent internaliza-
tion and recycling [11]. Both arms of this pathway are regulated by
several factors, including stimulation of cell surface receptors [12],
interaction with catenins [13], and activation of Rho small GTPases,
including RhoA, Rac, and Cdc42 [14–17]. The actions of Rho may
be dependent on the downstream phosphorylation of myosin light
chain, because ML-7, an inhibitor of myosin light chain kinase
(MLCK), can restore E-cadherin cell-cell junctions that have been
disrupted after transformation by Ras or Src [14,18].
There is a reciprocal relationship between E-cadherin function and
the activity of receptor tyrosine kinases (RTKs). The formation of
E-cadherin junctions reduces ligand-dependent activation of several
RTKs, including the epidermal growth factor receptor (EGFR) [19],
whereas mutation of E-cadherin increases EGF-induced Ras activa-
tion through a mechanism that may include stabilization of the
EGFR at the cell surface [20]. Conversely, EGFR activation destabi-
lizes the functional E-cadherin complex [21]. This inhibitory effect
of RTK activation on E-cadherin function may be caused by a direct
phosphorylation of components of the E-cadherin complex [21,22].
In addition to these direct effects, Ras-dependent signal transduction
downstream of RTK activation may also contribute to down-regulation
of E-cadherin. For example, inhibition of Ras can restore E-cadherin
expression in a variety of human cancer cells [23], whereas inhibition
of the extracellular signal–regulated kinase (ERK) mitogen-activated
protein kinase (MAPK) cascade that is downstream of Ras blocks
the ability of EGF to disrupt adherens junctions [24]. Ras signaling
can also lead to regulation of Rho small GTPases and thus control
of EMT [25]. In intestinal epithelial cells, for example, expression of
activated Ras is sufficient to disrupt E-cadherin through an ERK-
dependent pathway [9], which results in both suppression of its
transcription [26] and mislocalization from the cell surface [27]. En-
forced overexpression of E-cadherin is not able to restore epithelial
morphology to Ras-transformed intestinal epithelial cells as cell sur-
face localization of E-cadherin is not restored [27]. Nevertheless, ex-
pression of E-cadherin in MDA-MB-231 breast cancer cells, which
contain an activating mutation in K-Ras [28], is sufficient to promote
reversion to an epithelial morphology [26]. Further, overexpression
on E-cadherin suppresses invasiveness in a mouse mammary tumor
cell model [29].
In this study, we tested the ability of E-cadherin reexpression, in
combination with inhibitors of Ras-dependent signal transduction
pathways, to restore E-cadherin adherens junctions in models of
Ras-transformed breast epithelial cells. Our data showed that in cells
with moderate levels of activated Ras, expression of E-cadherin was
retained but mislocalized and that inhibition of the ERK MAPK cas-
cade was sufficient to restore adherens junctions and epithelial mor-
phology. In highly Ras-transformed cells, E-cadherin expression was
greatly reduced and not restored by inhibition of ERK MAPK. Re-
expression of E-cadherin did not restore adherens junctions unless
these cells were also treated with inhibitors of ERK MAPK activation
but not with inhibitors of other pathways downstream of Ras. When
both E-cadherin was reexpressed and ERK MAPK was inhibited, the
Ras-transformed cells showed restoration of E-cadherin cell-cell junc-
tions and reversion to an epithelial morphology.
Materials and Methods
Reagents
Dulbecco’s modified Eagle’s medium/F12, horse serum, PBS, human
EGF, sodium pyruvate solution, L-glutamine solution, Lipofectamine
2000, and antifade reagent were purchased from Invitrogen (Carlsbad,
CA). Dulbecco’s modified Eagle’s medium, trypsin/EDTA solution,
and penicillin-streptomycin were obtained from Cellgro (Herndon,
VA). Fetal bovine serum (FBS) was from HyClone (Logan, UT). Pro-
tease inhibitor cocktail tablets were obtained from Roche (Indianapolis,
IN). The MAPK kinase inhibitor PD184352 (CI-1040) was gener-
ously supplied by Pfizer, Inc (New York, NY). The MAPK kinase
inhibitor U0126, Rac1 inhibitor NSC23766, and MLCK inhibitor
ML-7 were purchased from Calbiochem (La Jolla, CA). Western
blot analysis detection reagents were purchased from GE Health-
care (Amersham, UK). Glutathione Sepharose 4B was purchased
from Amersham Biosciences (Uppsala, Sweden). 4′,6-Diamidino-2-
phenylindole was purchased from Molecular Probes (Eugene, OR).
Bovine serum albumin (BSA), dithiothreitol (DTT), hexadimethrine
bromide (polybrene), hydrocortisone, FITC-conjugated phalloidin,
the PI3 kinase inhibitor wortmannin, and other chemicals not other-
wise listed were obtained from Sigma (St. Louis, MO). Mouse anti–E-
cadherin, mouse anti–N-cadherin, Alexa Fluor 555 donkey antimouse,
and Alexa Fluor 633 goat antirabbit antibodies were purchased from
BD Biosciences (Bedford, MA). Rabbit anti–phospho-Akt(Ser473)
and rabbit anti–β-catenin antibodies were purchased from Cell Signal-
ing Technology (Beverly, MA). Mouse anti–H-Ras antibody was from
Calbiochem. Mouse anti–N-Ras, mouse anti-RhoA, rabbit anti-RhoB,
and rabbit anti-Cdc42 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse anti-Rac antibody was from
Upstate (Lake Placid, NY). Mouse anti–phospho-Erk1/2 antibody was
from Sigma. Mouse antitubulin antibody was obtained from Devel-
opmental Studies Hybridoma Bank (Iowa City, IA). Normal donkey
serum, normal goat serum, horseradish peroxidase (HRP)–conjugated
donkey antimouse IgG, and HRP-conjugated donkey antirabbit anti-
bodies were purchased from Jackson ImmunoResearch Laboratories,
Inc. (West Grove, PA).
Cell Lines and Culture
MCF10A human breast epithelial progression series of cells
(MCF10A, NeoT, AT1, and DCIS) were obtained from the Cell
Lines Resource (Karmanos Center Institute, Detroit, MI). MCF10A
cell lines stably expressing constitutively active H-Ras.D12 (H-Ras
MCF10A) or active N-Ras.D12 (N-Ras MCF10A) have been previ-
ously described [30] and were kind gifts from Dr. Hyeong-Reh Choi
Kim (Wayne State University, Detroit, MI). The MCF10A series of
cells and the retrovirus packaging cell line Hek293Twere cultured as
previously described [31].
Retrovirus Production and Infection
The retrovirus construct LZRS-GFP-hEcad that expresses human
E-cadherin and green fluorescent protein (GFP) and the control con-
struct LZRS-MS-GFP that only expresses GFP are derived from those
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previously described [32] and were generous gifts from Dr. Albert B.
Reynolds (Vanderbilt University, Nashville, TN). Packaging of retro-
viruses and infection of target cells were performed as described [31].
Briefly, Hek293T packaging cells were triply transfected with the virus
construct and the two packaging plasmids, pVPack-GP and pVPack-
VSV-G (Stratagene, La Jolla, CA). The viral broth was collected as
batches at time points of 36, 48, and 72 hours. The MCF10A and
derivative cells were infected at a low cell confluence of approximately
5% in the presence of 12 μg/ml polybrene, with approximately two
to three runs of infection every 24 hours to produce a final infection
efficiency that was approximately 95% by monitoring for GFP-positive
cells under fluorescent microscopy.
Immunocytochemistry
Cells were cultured on 12-mm round coverslips in 24-well plates
with 0.5 ml of culture medium per well. For immunocytochemical
staining, cells were subjected to the following treatments: fixation with
4% paraformaldehyde for 20 minutes; permeabilization with 0.5%
Triton X-100 for 10 minutes; further fixation with 95% ice-cold
EtOH for 10 minutes; quenching and washing with PBS containing
0.75% glycine for three times, 10 minutes each time; and blocking for
overnight at 4°C with immunofluorescent buffer (IF buffer; 130 mM
NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 0.1% BSA, 0.2% Triton
X-100, 0.05% Tween 20, pH 7.5). Then, the cells were stained for
2 hours with the first antibody diluted in IF buffer, washed with PBS
for three times, and stained for 1.5 hours with the fluorescent pigment–
conjugated second antibody diluted in IF buffer containing 5% nor-
mal serum from the same species of the animal as used for raising
the second antibody. As needed, FITC-phalloidin and 4′,6-diamidino-
2-phenylindole were included in the second antibody mixture to stain
the actin cytoskeleton and nuclei, respectively. The coverslips were
mounted onto slides with antifade reagent. Cells were imaged using
LSM 510 confocal microscope (Zeiss, Gottingen, Germany).
Western Blot Assays
Cells were cultured in growth medium on 35-mm tissue culture
plates to approximately 80% confluence. Then, fresh medium was
added with or without the presence of drugs, and the cells were cul-
tured for 24 hours. After briefly rinsing with PBS, the cells were
lysed in buffer: 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10 mM
sodium pyrophosphate, 2 mM EDTA, 1% Nonidet P-40, 1% 2-
mercaptoethanol, 10% glycerol, 2% sodium dodecyl sulfate, 50 mM
sodium fluoride, 0.2 mM sodium orthovanadate, 0.005% bromo-
phenol blue, and supplemented with protease inhibitor cocktail accord-
ing to the manufacturer’s instructions. The cell lysates were subjected to
brief sonication and heated for 5 minutes at 100°C. After SDS-PAGE,
the proteins were transferred onto nitrocellulose membranes, which
were blocked with 2% milk for 1 hour in TBS-T buffer: 25 mM
Tris-HCl, pH 7.4, 135 mM NaCl, 3 mM KCl, and 0.05% Tween
20. This blocking buffer was also used for the dilution of antibodies.
Small GTPase Activity Assay
GST-fusion proteins that bind to the active form of small GTPases
were used in this study to assay the activation state of Ras and Rho-
family proteins. GST-Raf-RBD was used to isolate GTP-bound
forms of H-Ras and N-Ras largely as previously described [33].
GST-PAK-PBD was used to isolate GTP-bound forms of Rac and
Cdc42 largely as previously described [34]. GST-Rhotekin-RBD,
which was a generous gift from Dr. Martin Schwartz (University of
Virginia), was used to isolate the GTP-bound forms of RhoA and
RhoB. Briefly, cells were cultured in growth medium with 10 μM
U0126, 1 μM PD184352, or vehicle (dimethylsulfoxide, DMSO)
for 24 hours and were lysed in 25 mM HEPES, pH 7.5, 100 mM
NaCl, 15 mM MgCl2, 0.5 mM EDTA, 5% glycerol, 1% Nonidet
P-40, 0.25% deoxycholate supplemented with 1 mM DTT, 4 μg/ml
aprotinin, 4 μg/ml leupeptin, 4 μg/ml pepstatin, and 1 mM phenyl-
methanesulfonyl fluoride before use. Lysates were collected, briefly soni-
cated, centrifuged for 5 minutes at 10,000g, and standardized for
protein content. Equal amounts of the GST-fusion protein beads were
mixed with each of the cell lysates and incubated with rotation at 4°C
for 1.5 hours to let the active form of GTPases to bind to the beads.
The beads were then collected by centrifugation and washed three
times with lysis buffer. The retained proteins were then subjected to
SDS-PAGE and Western blot assays.
Results
Ras-Driven Down-regulation of E-cadherin Expression
in Derivatives of MCF10A Breast Epithelial Cells
MCF10A cells are a spontaneously immortalized human breast
epithelial cell line that was developed from a patient who underwent
a reduction mammoplasty [35]. MCF10A cells are pseudodiploid,
form typical cobblestone epithelial sheets in monolayer culture (Fig-
ure 1A), and are used as a model of normal human breast epithelium
[36]. Stable transfection of MCF10A cells with an activated H-Ras.
V12 construct produced the MCF10AneoT (NeoT) line [37]. NeoT
cells retain an epithelial morphology in culture (Figure 1A) but
exhibit some aspects of the malignant phenotype in that they can
form xenograft lesions [38]. The validity of this model is based on
the widespread functional activation of Ras in human breast cancers
[28] owing to overexpressed growth factors and their receptors [39],
and the evidence that Ras-directed therapeutics may be useful in
breast cancer treatment [40], although Ras mutations per se are not
common. The relevance of this model is further supported by study
of gene expression signatures that define Ras pathway activation,
which confirm that Ras activation is prevalent in breast cancer and
predict sensitivity to therapeutics that target Ras signaling [41]. By
serial passaging of NeoT xenograft lesions in vivo, a more advanced
cell line was isolated and named MCF10.AT1 (AT1). AT1 cells
produce xenograft lesions with characteristics of atypical (grade 3)
hyperplasia [38] but show only a mild derangement of epithelial
morphology in vitro (Figure 1A). After further serial passages in vivo,
MCF10.DCIS.com (DCIS) cells were isolated. As xenografts, DCIS
cells initially form lesions with the characteristics of comedo ductal
carcinoma in situ, which may progress to invasive carcinoma over
time [42]. The DCIS cells exhibit a clear loss of epithelial organiza-
tion in vitro (Figure 1A) with a more fibroblast-like phenotype that is
characterized by less distinct cell-cell contacts.
In addition to the premalignant progression series of MCF10A,
NeoT, AT1, and DCIS cells, we also tested two further variants of
MCF10A cells that were made by retroviral-mediated overexpression
of activated H-Ras.D12 or N-Ras.D12 constructs [30]. Both of these
cell lines showed complete loss of epithelial morphology, with de-
creased cell-cell and cell-substrate attachment (the latter particularly
notable in N-Ras MCF10A cells), and an overall conversion to a
phenotype that is consistent with Ras transformation (Figure 1A).
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To test the relationship between Ras transformation and E-cadherin
in the MCF10A-derived cell lines, we assayed the expression of E- and
N-cadherin, small GTPases, and markers of Ras activation by Western
blot analysis (Figure 2A). The results show that there is a progressive
increase in the expression of H-Ras from MCF10A to DCIS cells that
is correlated with a modest reduction in the level of E-cadherin. The
very high levels of activated H-Ras and N-Ras expression in the H-Ras
MCF10A and N-Ras MCF10A cells are correlated with much more
profound loss of E-cadherin expression, although a low level of expres-
sion can be detected with prolonged exposures (Figure 2A). MCF10A
cells have a low level of N-cadherin expression, which is consistent
with previous reports [43] and is increased in H-Ras and N-Ras
MCF10A cells (Figure 2A). A switch from E-cadherin to N-cadherin
expression has been described as a feature of EMT and transformation
in several cancers [44].
The effect of activated Ras to down-regulate E-cadherin may be
through mechanisms that could involve activation of classic signaling
pathways downstream of Ras, such as ERK MAPK or PI 3-kinase/
Akt [45], and could also be mediated through regulation of Rho and
Rac proteins [17,25]. The activation level of ERK MAPK, which was
Figure 1. (A) Morphology of MCF10A cells and derivatives. Phase-contrast images showing the morphology of live MCF10A, NeoT, AT1,
DCIS, H-Ras MCF10A (H-Ras), and N-Ras MCF10A (N-Ras) cells. Scale bar, 40 μm. (B) Effects of Ras transformation and inhibition of
Ras-driven signaling pathways on the localization of E-cadherin. Cells were cultured on coverslips for 3 days in the presence of inhibitors
or vehicle (DMSO). Inhibitor concentrations were: U0126, 10 μM; wortmannin, 100 nM; NSC23766, 75 μM; ML-7, 25 μM. Cells were
fixed and processed for immunofluorescent detection of E-cadherin and confocal images are shown. Scale bar, 20 μm.
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highest in the DCIS, H-Ras, and N-Ras MCF10A lines, did correlate
well with both the increase in Ras expression and the decrease in
E-cadherin in the MCF10A derivatives (Figure 2B). The activation
level of Akt did increase in the progression series from MCF10A to
DCIS cells, but was not elevated in the H-Ras and N-Ras MCF10A
lines, and also correlated less strongly with the reduction in E-cadherin
(Figure 2B). The expression levels of RhoA and Rac1 did not consis-
tently change with Ras transformation status or correlate with down-
regulation of E-cadherin (Figure 2B).
Restoration of E-cadherin Localization in DCIS Cells Treated
with an Inhibitor of ERK MAPK Activation
To determine whether alterations in epithelial morphology in the
MCF10A derivatives were correlated with changes in the cell surface
expression of E-cadherin, we performed confocal immunofluorescence
to localize E-cadherin (Figure 1B). The results show that prominent
cell surface localization of E-cadherin is maintained during premalig-
nant progression from MCF10A cells through NeoTand AT1 variants,
which correlates with the maintenance of epithelial morphology (Fig-
ure 1). In DCIS cells, which have somewhat reduced total E-cadherin
expression (Figure 2), there is markedly less E-cadherin at the cell sur-
face but an apparent increase in intracellular E-cadherin (Figure 1B,
top row). In the H-Ras and N-Ras MCF10A lines, there is much less
E-cadherin expression (Figure 2), and what remains is not at the cell
surface but is localized intracellularly (Figure 1B, top row).
To begin investigation of which pathways downstream of Ras acti-
vation may be required for the changes in E-cadherin in the MCF10A
derivative cell lines, we compared the localization of E-cadherin in
control (vehicle-treated) cells with those treated with selective inhibi-
tors of MAPK kinase (U0126), PI 3-kinase (wortmannin), activation
of Rac (NSC23766), or MLCK (ML-7). None of these treatments
had any effect on the low levels of E-cadherin in H-Ras and N-Ras
MCF10A cells (Figure 1B). Similarly, these treatments had little ob-
servable effect on the cell surface expression of E-cadherin that was
present in MCF10A, NeoT, or AT1 cells, although ML-7 did repro-
ducibly induce an additional increase in E-cadherin at a site that ap-
peared to be perinuclear. The most striking effects occurred in DCIS
cells, where U0126 in particular, and to a lesser extent ML-7, induced
an increase in the cell surface localization of E-cadherin.
Restoration of Epithelial Morphology in DCIS Cells Treated
with Inhibitors of ERK MAPK Activation
To investigate the effects of ERK MAPK inhibition on cellular mor-
phology in more detail, we compared the effects of U0126 to a second,
more potent inhibitor, PD184352 [33] on E-cadherin localization
and the actin cytoskeleton (Figure 3). MCF10A cells have an or-
ganized actin cytoskeleton that is characterized by a cortical ring,
and that structure is maintained and perhaps intensified by inhibition
of ERK MAPK activation (Figure 3). In addition, both U0126 and
PD184352 induce an apparent increase in size of the MCF10A cells
that is likely caused by increased cell spreading. DCIS cells do not
show the same organization of the actin cytoskeleton under control
conditions, and there is a limited effect of U0126 on this parameter,
but PD184352 is able to completely restore the cortical actin organi-
zation and cell-cell localization of E-cadherin and produces cells that
have a clearly epithelial morphology (Figure 3). Although there is no
effect of either U0126 or PD184352 on E-cadherin localization in the
H-Ras and N-Ras MCF10A cells, inhibition of ERK MAPK activa-
tion does produce a striking change in the actin cytoskeleton. The cells
are clearly more spread and have prominent actin stress fibers after
inhibition of MAPK kinase, with again a stronger effect induced by
PD184352 (Figure 3). Interestingly, the H-Ras and N-Ras MCF10A
cells seem to make more cell-cell contacts after inhibition of ERK
MAPK activation, although E-cadherin localization is not restored
(Figure 3).
To further investigate the effects of the MAPK kinase inhibitors
on cell spreading, we performed experiments on subconfluent cells
(Figure 4). The results show that both U0126 and PD184352 greatly
Figure 2. (A, B) Overexpression of active H- and N-Ras decreases E-cadherin and activates ERK MAPK. MCF10A and derivative cells
were cultured in growth medium. Cell lysates were subjected to Western blot assays as indicated. Two exposures are shown for the
E-cadherin blots to reveal both the variation that occurs during progression from MCF10A to DCIS cells and the low level of E-cadherin
expression that remains in the H-Ras and N-Ras MCF10A cells. Tubulin was probed to verify equal loading.
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increase the spreading of the H-Ras and N-Ras MCF10A cells and
induce prominent increases in actin stress fibers. Notably, these data
also show that the increased stress fibers do not depend on cell-cell
contacts because they are found even in isolated cells (Figure 4).
Enforced Expression of Exogenous E-cadherin Correlated with
Up-regulated Expression of Endogenous β-catenin
Another potential method to restore epithelial morphology to trans-
formed cells is to reintroduce expression of E-cadherin [27,46]. In the
Figure 3. The MAPK kinase inhibitor PD184352 restores E-cadherin cell-cell junctions and cortical actin organization in DCIS cells. Cells
were cultured on coverslips in growth medium containing 1 μM of PD184352, 10 μM of U0126, or vehicle (DMSO) for 3 days. Then the
cells were fixed and stained for actin cytoskeleton (green), nuclei (blue), and processed for immunofluorescent detection of E-cadherin
(pink). Confocal fluorescent images are shown. Scale bar, 30 μm.
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present study, we used retroviral transduction of the MCF10A cells
and derivatives and observed overexpression of E-cadherin in all cell
lines to approximately the same level (Figure 5). The retroviral con-
struct used, LZRS-GFP-hEcad, has both E-cadherin and GFP coding
sequences with an internal ribosome entry site between them. This
arrangement allows bicistronic expression of both E-cadherin and
GFP, with the latter being a reporter gene for E-cadherin expression.
Cells infected with a GFP-only construct were used as control. The
degree of overexpression of E-cadherin obtained was approximately
two-fold over that in control MCF10A cells. Interestingly, overexpres-
sion of E-cadherin correlated with up-regulation of β-catenin expres-
sion, but had no effect on the activation of ERK MAPK (Figure 5).
In MCF10A, NeoT, AT1, and DCIS cells, the increase in β-catenin
seems modest compared to the substantial levels of protein in control,
GFP-infected cells. In H-Ras and N-Ras MCF10A cells, the increase
in β-catenin induced by reexpression of E-cadherin, although of a simi-
lar magnitude, produces a much greater relative change over the mini-
mal levels present in control, GFP-infected cells (Figure 5).
Both Reexpression of E-cadherin and Suppression of ERK
MAPK Kinase Activity Were Required to Restore E-cadherin
Cell-cell Junctions in H-Ras and N-Ras MCF10A Cells
In our study, the H-Ras and N-Ras MCF10A cell lines have very
low expression levels of E-cadherin (Figure 2), and, although in-
hibitors of ERK MAPK activation cause increased cell spreading
(Figures 3 and 4), they do not restore E-cadherin cell-cell junctions
(Figure 4). We therefore tested whether reexpression of E-cadherin
would reverse the mesenchymal phenotype back to an epithelial
phenotype, either as a single intervention or in combination with
MAPK kinase inhibition (Figure 6). The results show that reexpres-
sion of E-cadherin restored neither the E-cadherin junctions nor the
epithelial morphology to H-Ras and N-Ras MCF10A cells (Figure 6,
top row). The E-cadherin protein remained predominantly intracellular
after overexpression. However, when these cells were induced to ex-
press E-cadherin and treated with MAPK kinase inhibitors U0126
or PD184352, the E-cadherin protein was targeted to cell-cell junc-
tions, with less remaining localized intracellularly (Figure 6).
Figure 4. Inhibition of MAPK kinase induces cell spreading in Ras-transformed MCF10A cells. H-Ras and N-Ras MCF10A cells were
cultured on coverslips for 3 days in the presence of U0126 (10 μM), PD184352 (1 μM), or vehicle (DMSO). Then, the cells were fixed
and stained for actin cytoskeleton (green), nuclei (blue), and processed for immunofluorescent detection of E-cadherin (pink). Confocal
fluorescent images are shown. Scale bar, 30 μm.
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Figure 6. Both reexpression of E-cadherin and inhibition of MAPK kinase are required to restore E-cadherin cell-cell junction in H-Ras and
N-Ras MCF10A cells. H-Ras and N-Ras MCF10A cells were infected with retroviruses to reexpress E-cadherin plus GFP or the expression
of only GFP as the control. The cells were cultured on coverslips in the presence of U0126 (10 μM), PD184352 (1 μM), or vehicle (DMSO)
for 3 days. The cells were then fixed and stained for nuclei (blue) and processed for immunofluorescent detection of E-cadherin (pink).
The infected cells are green. Confocal fluorescent images are shown. Scale bar, 30 μm.
Figure 5. Enforced expression of E-cadherin in MCF10A and derivative cells. MCF10A and derivative cells were infected with retro-
viruses encoding E-cadherin plus GFP (label: Ecad) or GFP alone (label: GFP). After 5 days of infection, cell lysates were subjected
to Western blot assay and probed for E-cadherin, β-catenin, and phospho–ERK1/2. Longer exposures of the E-cadherin blot reveal
low levels of expression in the GFP-control condition for H-Ras and N-Ras MCF10A cells that are consistent with the levels shown in
untransfected H-Ras and N-Ras MCF10A cells in Figure 2 (not shown). Tubulin was probed to verify equal loading.
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To further investigate the pathways downstream of Ras that may
contribute to the regulation of E-cadherin localization, we tested
whether wortmannin, NSC23766, or ML-7 could induce exogenous
E-cadherin to localize at cell-cell junctions (Figure 7). The results show
that exogenous E-cadherin is strongly localized to the cell surface
only in MCF10A cells, with a mix of cell surface and intracellular
localization in DCIS cells. The peripheral localization of exogenous
E-cadherin is somewhat reduced by the pathway inhibitors, which tend
to produce an increase in the intracellular localization of E-cadherin
(Figure 7, left columns). Similarly, but in contrast to the effects of
U0126 and PD184352 (Figure 6), none of these inhibitors caused
the localization of expressed E-cadherin to the cell surface of H-Ras
and N-Ras MCF10A cells (Figure 7).
Inhibition of ERK MAPK Activation Affects a Broad Panel
of Cell Adhesion-related Proteins and Pathways
Our results showed that inhibition of ERK MAPK kinase activation
promotes the reversion to epithelial morphology in Ras-transformed
MCF10A cells. We confirmed that the two MAPK kinase inhibitors
efficiently down-regulated ERK activation under the conditions used
in this study (Figure 8A). Because ERK MAPKs control many down-
stream events, we further characterized the treated cells to find effects
Figure 7. Inhibition of PI3-kinase, Rac, or MLCK does not restore E-cadherin cell-cell junctions in cells with E-cadherin overexpression.
Cells were infected with retroviruses to reexpress E-cadherin plus GFP or the expression of only GFP as the control. The cells were
cultured on coverslips in the presence of PI3-kinase inhibitor wortmannin (100 nM), Rac inhibitor NSC23766 (75 μM), MLCK inhibitor ML-7
(25 μM), or vehicle (DMSO) for 3 days. The cells were then fixed and stained for nuclei (blue) and processed for immunofluorescent de-
tection of E-cadherin (pink). The infected cells are green. Confocal fluorescent images are shown. Scale bar, 30 μm.
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that may contribute to the reversion of mesenchymal morphology.
One possibility could be that MAPK activity may up-regulate the ex-
pression level of the zinc-finger family transcription factor Slug that
suppresses E-cadherin expression [47,48], and thus, inhibition of
MAPK kinase could enhance the level of E-cadherin. Such an effect
has been seen for U0126 or PD98059 treatment of colon cancer cells,
for example [47]. Our results, however, show that treatment with
U0126 led to only a minimal increase in the expression of E-cadherin
in H-Ras MCF10A cells but with no effect in MCF10A, DCIS, or
N-Ras MCF10A cells (Figure 8B). PD184352, which is more effective
than U0126 in the reversion to normal epithelial morphology (Fig-
ure 3), did not increase the expression of E-cadherin (Figure 8B).
Figure 8. Inhibition of MAPK kinase modifies the expression of adhesion-associated proteins in Ras-transformed MCF10A cells. Cells
were cultured in growth medium and treated with 10 μM of U0126 (U0), 1 μM of PD184352 (PD), or vehicle (DMSO) for 24 hours. Cell
lysates were subjected to direct Western blot assay (A, B, C). Tubulin was probed to verify equal loading. Densitometric scans of results
for β-catenin expression were collected from three independent experiments (D). Data shown are mean ± SEM of the signal in paired
comparisons of samples treated with vehicle (set to 100% for each cell line) and with U0126 or PD184352. Increases in β-catenin in
H-Ras and N-Ras MCF10A cells treated with inhibitors of ERK MAPK activation were significant (P < .05).
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These data show that MAPK kinase inhibitors are effective in restoring
E-cadherin localization to cell-cell junctions (Figures 3 and 6) in the
absence of a significant effect on E-cadherin expression levels
(Figure 8B). Another potential mechanism for phenotypic reversion
could be the loss of expression of mesenchymal markers. In this case,
however, there was little effect of the MAPK kinase inhibitors on the
expression of N-cadherin in the Ras-transformed cells (Figure 8B). Al-
though there was no consistent effect of the MAPK kinase inhibitors
on the expression of the cadherins, there was a consistent but modest
increase in the expression of β-catenin in H-Ras and N-Ras MCF10A
cells (Figure 8C ). Quantification of these results showed that both
U0126 and PD184352 caused an approximate doubling of the level
of β-catenin in the H-Ras and N-Ras MCF10A cells but no change in
the expression of β-catenin in MCF10A or DCIS cells (Figure 8D).
Another direct, albeit unlikely, possibility for how a treatment
could reverse the effects of Ras transformation would be if the acti-
vation level of Ras was reduced. We therefore tested whether inhibi-
tion of ERK MAPK activity affected the level of active Ras.GTP in
the MCF10A and derivative cells (Figure 9A). We found no effect of
PD184352 to reduce the level of H-Ras.GTP in NeoT, AT1, DCIS,
or H-Ras MCF10A cells or of N-Ras.GTP in N-Ras MCF10A cells.
There was, however, an opposite and modest effect of PD184352
to increase the very low level endogenous H-Ras.GTP in MCF10A
cells. This result may suggest that PD184352 blocks a feedback in-
hibitory pathway that acts to limit Ras activation in this cell type.
Inhibition of MAPK kinase induced cell spreading and an increase
in actin stress fibers in H-Ras and N-Ras MCF10A cells (Figures 3
and 4). Because these results implicated changes in the actin cyto-
skeleton, we further tested for effects on the Rho family of small
GTPases that have been well-documented to be regulators of epithe-
lial cell adhesion, shape, polarity, and motility [49–52]. Our results
show that the activation levels of Rac and Cdc42 are generally con-
sistent across the whole series of cells tested and also are insensitive to
inhibition of MAPK kinase (Figure 9A). Active levels of RhoA were
only detectable in H-Ras and N-Ras MCF10A cells and consistently
declined after PD184352 treatment (Figure 9, A and B). Active levels
Figure 9. Inhibition of MAPK kinase modifies the activation of Rho-family small GTPases in Ras-transformed MCF10A cells. Cells were
cultured in growth medium and treated with 1 μM of PD184352 (PD) or vehicle (DMSO) for 24 hours. Cell lysates were subjected to
isolation of activated forms of Ras, Rac, Cdc42, or Rho, as indicated (A). Tubulin was probed to verify that equal lysate had been used in
the small GTPase activity assays. Densitometric scans of results for the activation of RhoA (B) and RhoB (C) were collected from three
independent experiments. Data shown are mean ± SEM of the signal in paired comparisons of samples treated with vehicle (set to
100%) and with PD184352. Inhibition of RhoA and RhoB activation by PD184352 was significant (P < .01).
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of RhoB were only detectable in N-Ras MCF10A cells and also de-
clined after PD184352 treatment (Figure 9, A and C ).
Discussion
Because E-cadherin plays a central role in the maintenance of the
architecture and function of normal breast epithelial tissue, engineer-
ing the expression of E-cadherin in breast cancer cells that have lost
its functional expression could be a new approach to the disease. For
example, there could be mechanisms to induce reexpression of the
endogenous E-cadherin. E-cadherin expression can be controlled at
the transcriptional level by enhancing transcription factors AML1,
Sp1, p300, and HNF3 [46] and by transcriptional repressors Snail,
Slug, SIP-1, and Twist [26,53–55]. Slug, for example, can suppress
E-cadherin expression in Ras transformation of intestinal epithelial cells
[26] and in several breast cancer cell lines [7]. Knock-down of Slug
by siRNA in Ras-transformed intestinal epithelial cells [26] and ex-
pression of the E-cadherin–enhancing transcription factor HNF3
or inhibition of DNA methylation in breast cancer cell lines [46]
lead to restored E-cadherin expression and promote near-complete
rescue of the epithelial morphology. Similar reversion of EMT in
Ras-transformed breast epithelial cells can be induced by inhibition
of NF-κB [56]. Another approach has been to directly reexpress
E-cadherin. In MDA-MB-231 breast cancer cells, reexpression of
E-cadherin leads to restoration of E-cadherin cell-cell junctions and
reversion to epithelial morphology [26], impaired EGF and IGF-1
signaling [19], and more organized growth in three-dimensional
culture [57]. In the current study, we found that reexpression of
E-cadherin was not effective in reversing EMT in MCF10A cells
that had been transformed by the high-level expression of activated
H-Ras or N-Ras. This result is consistent with that reported in H-
Ras–transformed intestinal epithelial cells [27]. In that report and in
the current study, reexpressed E-cadherin did not relocalize to the cell
surface but remained predominantly intracellular. The current study
may be the first to demonstrate the effects of N-Ras transformation
on E-cadherin junctions in human breast epithelial cells but is con-
sistent with a report that activated N-Ras can cause EMT in a mouse
mammary cell line [58].
In this study, higher levels of activated Ras produced more dra-
matic transformation of breast epithelial cells that was manifested
at both morphologic and molecular levels. It is likely that the activa-
tion of the multiple effector pathways downstream of Ras may require
different threshold levels of Ras activation, and thus that changes in
the expression level of active Ras may trigger varying panels of down-
stream signaling events. For example, in keratinocytes, a lower level of
v-Ha-Ras expression produces benign tumors, whereas a higher level of
v-Ha-Ras causes malignant transformation [59]. In cells transformed
by oncogenic N-Ras, the level of N-Ras expression determines acti-
vation of specific downstream pathways [60]. Lower levels of N-Ras
expression couple to the Ral-GDS and PI 3-kinase pathways to trigger
the mislocalization of the CDK inhibitor p27Kip1, leading to CDK
activation, but do no affect the TGF-β/Smad2/3 pathway. In contrast,
higher levels of N-Ras expression not only induce the CDK pathway
but also couple to the activation of MEK/ERK MAPK signaling that
leads to inactivation of the TGF-β/Smad2/3 pathway [60]. These re-
ports and our data suggest that a higher level of activated Ras expres-
sion may trigger more downstream pathways than a lower level of Ras
expression and lead to stronger and more malignant transformation.
Thus, the therapeutic reversion of cells that have undergone malignant
transformation caused by higher levels of oncogene expression may
require effective block of more than one pathway. For example, in
the case of the present study, both inhibition of MAPK kinase and
enforced expression of E-cadherin were required to restore adherens
junctions in the H-Ras and N-Ras MCF10A cells.
The results of the current study and published work [27] sug-
gest that Ras transformation not only can lead to the suppression
of E-cadherin expression but may also prevent the formation of
functional E-cadherin junctions by preventing the appropriate sub-
cellular localization of E-cadherin. We have found that inhibition of
ERK MAPK activation is effective in restoration of E-cadherin junc-
tions in DCIS cells, which have a modest level of active Ras ex-
pression. Similarly, inhibition of ERK MAPK activation can induce
reexpressed E-cadherin to locate to cell-cell junctions in H-Ras and
N-Ras MCF10A cells. These results are again consistent with the ef-
fect of U0126 to cause relocalization of E-cadherin to the cell surface
in Ras-transformed intestinal epithelial cells [9]. In both DCIS cells,
where significant E-cadherin expression remains, albeit at an intracel-
lular location, and in H-Ras and N-Ras MCF10A cells infected with
retroviruses encoding E-cadherin, the effect of MAPK kinase inhibi-
tion is predominantly on the relocalization of E-cadherin. We have
investigated several potential mechanisms that could drive this effect.
For example, inhibition of ERK MAPK activation caused a modest
increase in the expression of β-catenin, which, because it can sta-
bilize functional E-cadherin complexes at the cell surface [13], could
contribute to the response. Whereas this could be a factor in the
DCIS cells, it seems unlikely to explain the relocalization of expressed
E-cadherin in the H-Ras and N-Ras MCF10A cells, as the reexpression
of E-cadherin itself produces a larger increase in expression of β-catenin
but does not restore the adherens junctions. Another potential and
related mechanism could be through a reduction in N-cadherin ex-
pression so that the β-catenin could be restored to complexes with
E-cadherin, but N-cadherin expression was not reduced in the MAPK
kinase inhibitor–treated cells.
E-cadherin localization is also regulated by the activation of Rho
family small GTPases. RhoA, Rac, and Cdc42 have roles in the
establishment and maintenance of E-cadherin cell junctions [15–
17] and also in the dysregulation of E-cadherin localization in Ras-
transformed cells [14,25]. The connection between Ras and the
Rho GTPases seems to be cell type–dependent. For example, in colon
carcinoma cells, Ras-stimulated ERK activity promotes Rac activa-
tion but inhibits Rho activation [61]. In contrast, in Madin-Darby
canine kidney (MDCK) cells, Ras-stimulated ERK activity inhibits Rac
activation but promotes Rho activation [25]. Our results in MCF10A
cell derivatives do not reveal any changes in Rac1 expression or acti-
vation in response to either Ras transformation or inhibition of ERK
MAPK activation. Further, an inhibitor of Rac activation had no ef-
fect on relocalization of E-cadherin. Thus, Rac1 is not likely to be a
mediator of either the dysregulated or the restored E-cadherin locali-
zation in this study. Similarly, we did not record any changes in Cdc42
activation in response to Ras transformation or inhibition of ERK
MAPK activation.
In contrast to the lack of evidence for a role for Rac or Cdc42 in
the relocalization of E-cadherin, we found several effects that are re-
lated to Rho, including activation of RhoA in H-Ras MCF10A cells
and activation of both RhoA and RhoB in N-Ras MCF10A cells.
This may be the first report of activation of RhoB in response to
activated N-Ras and provides some contrast to a previous report that
activated N-Ras suppresses the expression of RhoB [62]. It is not
likely that RhoB activation plays a specific role in the localization of
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E-cadherin, because the dysregulation and restoration of E-cadherin
junctions occur similarly in H-Ras and N-Ras MCF10A cells that
are distinct in their RhoB activation status. There are, however, differ-
ences in the invasiveness of H-Ras and N-Ras MCF10A ([30] and our
unpublished observations) that may be related to RhoB. Activation of
both RhoA and RhoB was reduced by inhibition of ERK MAPK ac-
tivation. Thus, increased Rho activation in the Ras-transformed cells
correlates with profound disruption of E-cadherin junctions, whereas
reduced Rho activation after inhibition of MAPK kinase correlates
with the relocalization of reexpressed E-cadherin to the cell surface.
Inhibition of Rho function and downstream signaling, e.g., by inhibi-
tion of MLCK with ML-7 [63], has previously been shown to restore
E-cadherin localization in MCF10A cells transfected with activated
H-Ras [14]. Although we did not find any such effect of ML-7 in
the H-Ras and N-Ras MCF10A cells, ML-7 did have some modest
ability to restore E-cadherin localization in DCIS cells. It may be that
the ability of ML-7 to restore E-cadherin localization is dependent on
a relatively low level of expression of activated Ras (such as is found in
DCIS cells). Notably, even when E-cadherin was reexpressed in H-Ras
and N-Ras MCF10A, ML-7 was still not able to restore its localization
to the cell surface.
The effects of Rho activation on epithelial morphology vary with
the cell models studied. For example, in another model of MCF10A
cells transfected with activated H-Ras, Rho activity is required for the
mesenchymal contractility and motility, and inhibition of Rho by a
dominant-negative mutant of RhoA partially restores normal epithe-
lial phenotype [14]. However, in the same cell model, Rho activity is
also required for normal cell-cell adhesion junction formation and
maintenance, and blockage of Rho activity by C3 exotransferase com-
pletely disrupts E-cadherin junction [14]. In human keratinocytes and
MDCK cells, Rho is also required for the establishment of cadherin-
dependent cell-cell junction [15,64]. In contrast, activation of Rho in
MDCK cells can also result in EMT [65]. The discrepancies between
these reports may come from methodological issues, e.g., C3 exotrans-
ferase, which is a potent Rho inhibitor, inhibits several Rho isoforms
(RhoA, RhoB, and RhoC), and dominant-negative RhoA may also be
able to diminish the activation of other isoforms. RhoB, for example,
clearly has distinct cellular functions [49,66,67]. In the H-Ras and
N-Ras MCF10A cell models in this study, increased RhoA activity
may contribute to the fibroblastoid phenotype. Mitogen-activated pro-
tein kinase kinase inhibition induced a flattened cell morphology with
thick, dense stress fibers that were independent of cell confluency.
These thick stress fibers are quite different from the fine actin mesh
in normal MCF10A cells. This observation is consistent with results
from U0126-treated human colon carcinoma cells, which also display
flattened morphology and remarkable stress fibers [61]. The difference
between these results is that in the colon carcinoma cell lines, the stress
fibers correlate with enhanced Rho activity after MAPK kinase inhibi-
tion. In the current study, MAPK kinase inhibition induced a decrease
in activation of RhoA (and also RhoB). However, even after MAPK
kinase inhibition, there was still a substantial level of Rho activity re-
maining compared to the parental MCF10A cells. It is possible that
this remaining Rho activity will be required for the formation of the
observed stress fibers.
Overall, our results suggest that the ability to restore epithelial mor-
phology and E-cadherin adherens junctions in Ras-transformed breast
epithelial cells is dependent on the degree of expression of activated
Ras. In cells that express lower levels of activated Ras and retain some
E-cadherin expression, the relocalization of that E-cadherin by inhibi-
tion of the ERK MAPK pathway is very effective in restoring the
adherens junctions. In cells with a more marked Ras-transformed
phenotype that is characterized by a strong activation of RhoA, both
reexpression of E-cadherin and inhibition of ERK MAPK are required
to restore epithelial morphology and E-cadherin cell-cell junctions.
The ability to restore adherens junctions has been proposed to be of
potential significance as a cancer therapy, but evidence suggests that
ductal breast carcinomas, which often retain E-cadherin expression,
have a worse prognosis than lobular breast carcinomas that typically
lack E-cadherin expression [1]. Further, although loss of E-cadherin
can occur in the metastasis of ductal carcinoma to the pancreas, ex-
pression can be maintained in metastases to other sites [5], and it
has been reported that increased E-cadherin expression is associated
with metastasis to bone [68]. Overall, it is likely that there is a complex
relationship between E-cadherin expression and breast cancer, with
dynamic changes at different stages of tumor progression [1]. Because
inhibition of MAPK kinase has been suggested as a potential thera-
peutic approach to breast cancer [69], it will be important to deter-
mine whether such changes in E-cadherin occur in animal models
and patient samples.
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